Login to Your Account



Threshold Pharma halts tarloxotinib development; sees revival in evo, preclinical TH-3424

By Michael Fitzhugh
Staff Writer

Friday, September 30, 2016

Threshold Pharmaceuticals Inc. said it would discontinue development of EGFR-targeted tarloxotinib after the oncology candidate fell short of its expectations in dual phase II proof-of-concept trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription